Newsletter sign up

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.


ADC University Our services

ADC Review
is made possible by:




PEER-REVIEWED ARTICLES

World ADC Berlin (Germany)

The approval of Besponsa and re-approval of Mylotarg has injected huge excitement into the ADC field. Now with 4 approved drugs, over 65 candidates in clinical development and many more in preclinical development, ADCs are rapidly living up to their name – “magic bullets”.

Yet the narrow therapeutic index of ADCs means developing a clinically effective ADC is not without it’s challenges. There are more ADCs in clinical development than ever, continuous innovation in ADC technology and rapid advances in manufacturing processes readying for commercialisation. All this  means there is a lot to be distilled at World ADC Berlin 2018.

Now in it’s 8th year, World ADC Berlin is Europe’s leading antibody-drug conjugate conference. Across three days, this comprehensive three streamed programs will cover every element of ADCs from discovery, development, manufacturing and clinical.

This is the forum ADC drug developers converge at for three days to immerse themselves in the latest ADC science to enable the development of more clinically safe and efficacious ADCs.


Use promotional code ADCR10 to receive a 10% discount off the current price – click here to register online


Americas Antibody Congress 2017

FRESH DATA. EXPERT SPEAKERS. DEEP CONTENT.

This May, researchers from pharma, academia, and biotech will descend on San Diego for two days of networking and content on the challenges to the antibody industry presented by the increased demand for antibody drugs to fight chronic illnesses.

With demand comes innovation. The only antibody event with new data and non-repetitive talks as a requirement to speak, Americas Antibody Congress 2017 will feature sessions on New Data in Antibody Discovery, New Data in Clinical and Commercial Development, and the therapeutic areas of Infectious Diseases and Oncology.

Download the brochure

Click here tot register


 

World Immunotherapy Congress USA 2017

Discover. Develop. Get to market. For Biotech, Pharma, and Their Partners.

The demand for innovation in immunotherapy can only grow, and new breakthroughs are needed if success rates are to continue. That’s why World Immunotherapy Congress is coming to the USA after an acclaimed launch in Europe. This inaugural event will bring together the brightest and best minds in pharma, biotech, government and academia to build on the development and commercialization of new immunotherapy treatments.

Co-located with the Americas Antibody Congress, Immunotherapy World Congress USA features 2 days of in-depth case studies and discussions around Cell Therapy Strategies, Pre-Clinical Development and Innovative Therapeutic Approaches presented by our partners from biopharma and academia.

Click here to register.


 

CPhI | Pre-Connect Congress 2017

CPhI’s Pre-Connect Congress is the ‘Pharma Leaders’ Destination’ – a one day Congress taking place the day before the CPhI Worldwide Exhibition and covering the latest trends and developments in Pharma across a variety of sectors.

The Pre-Connect Congress is the only event to cover the full spectrum of the Pharma value chain.

Join us in Frankfurt on 23rd October for a series of thought provoking presentations, interactive panel discussions and dedicated networking opportunities, helping you to do better business in Pharma.

CPhI North America


Coming to Philadelphia, PA, USA May 16-18, 2017 is the only event which offers you access to the complete North American pharmaceutical supply chain – CPhI North America – alongside the leading fine & specialty chemical event – InformEx. Source your business solutions with 450+ suppliers, network with 6,000+ industry players, and stay ahead of industry trends with the first-ever Connect Conference featuring 8 tracks or at one of the show floor presentations – all under one roof! To learn more, go to cphinorthamerica.com or informex.com today!

CPhI North America
CPhI North America is the only event in North America to offer you access to the complete pharma supply chain. From fine chemicals to pharma ingredients to finished formulations to packaging – all of your business solutions are under one roof! Taking place in Philadelphia, PA, USA May 16-18, 2017 this is your opportunity to source products and services from 450+ suppliers, network with 6,000+ industry players, and stay ahead of industry trends with the first-ever CPhI Connect Conference featuring 40+ hours of cutting-edge content or at one of the show floor presentations – all under one roof! To learn more, go to cphinorthamerica.com today!

InformEx
InformEx, the leading fine & specialty chemical event in North America for 32+ years, is taking place in Philadelphia, PA, USA May 16-18, 2017. This is your opportunity to source products and services from 150+ suppliers, network with 6,000+ specialty chemical and pharma industry players, and stay ahead of industry trends with the first-ever InformEx Connect Conference featuring 40+ hours of cutting-edge content or at one of the show floor presentations – all under one roof! To learn more, go to informex.com today!

Click here to attend.



7th Annual World ADC Berlin 2017

The last 12 months has seen a staggering amount of progress in ADCs.

There are now 50+ compounds in the clinic; with approval of Pfizer’s Inotuzumab Ozogamicin expected later this year. Coupled with this, there is a bulging preclinical pipeline of 92 ADCs and counting.

In 2017, 300+ of the leading ADC minds will descend on the 7th Annual World ADC Berlin meeting (20-22 February) to share experiences, data and insights on how to develop the next generation of clinically impactful ADCs. Across three streams, every element of ADC development is addressed providing you with an unrivalled forum for learning.

The 2017 World ADC Berlin program has been designed to reflect these progressive innovations developing next-generation ADCs.

The meeting will be held in the Maritim proArte Hotel Berlin,  Friedrichstraße 151,  Berlin,  10117, Germany

SMi’s 6th Annual Conference: Antibodies & Antibody-drug Conjugates

SMi is proud to present their 6th Annual Antibodies and Antibody-drug Conjugates Conference, being held at the Copthorne Tara Hotel, London, UK on the 9th – 10th April 2018.

With an every-growing industry, the market is expected to reach USD 30 Billion by 2023.


Read on to gain your exclusive discount code to attend SMi’s 6th Annual Conference: Antibodies & Antibody-drug Conjugates


Antibodies and antibody-drug conjugates or ADCs have the potential to make a ground-breaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.

Join us this April 2018, as SMi’s ADC Summit conference brings together industry experts from leading life science and pharmaceutical companies. Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.



How Will You Benefit?

  • Network and learn from leading professionals such as or chairs and key speakers
  • Chairs for 2018:
    • Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma
    • Rakesh Dixit, Vice President and Global Head Biologics Safety Assessment, Medimmune
  • Key Speakers Include:
    • Robert Lyon, Senior Director, Seattle Genetics
    • Arnaud Tiberghien, Scientist II, Spirogen
    • Alison Betts, Associate Research Fellow, Pfizer
    • Thomas Pillow, Senior Scientist, Genentech
    • Andreas Pahl, CSO, Heidelberg Pharma
    • Carlo Boutton, Director of Technology, Ablynx
  • Some Featured Highlights will include:
    • Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.
    • Discover new and novel payloads, expanding the ADC landscape:
      • Antibody Targeted Amanitin Conjugates (ATACs) and
      • Minorgroove binding DNA-interactive molecules
    • Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.
    • Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumors.
    • Design principles for maximizing the drug delivery efficiency and therapeutic index.

Click here to view the full agenda.


Discount Code

Exclusive discount code for the readers of ADC Review | Journal of Antibody-drug Conjugates: UK £100 off using code:

ADCREVIEW100



 

CAR-T Congress, Boston, USA | March 20 – 22, 2018

CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematologic malignancies…is CAR-T therapy what we’ve been waiting for?
Join 18+ thought-leaders from biotech, big pharma, academia and the wider service community on 20th – 22nd March 2018 to address the challenges and opportunities of CAR-T therapies.

  • Hear first-hand results from unpublished human and clinical studies
  • Explore the challenges of the tumour microenvironment
  • Understand new approaches to scalability & streamlined cell therapy
  • Discover the next generation of immunotherapy and alternate cell constructs
  • Take advantage of the Commercialization Day and network and share knowledge to understand the commercial opportunities of CAR-T

Hear from top speakers including Ziopharm, Juno Therapeutics, Moffitt Cancer Center, Perelman School of Medicine, University of Pennsylvania and more. Join the conversation and learn more about the future of cell therapy.

To find out more, Click here.


 

Antibody–Drug Conjugates: Oncology and Beyond

Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.


Organizers  Speakers
Gene Dubowchik, Ph.D,
Bristol-Myers Squibb
Philip E. Brandish, Ph.D,
Merck & Co.
Lynn M. Abell, Ph.D,
Bristol-Myers Squibb
Ryan Fleming, Ph.D,
MedImmune
Pamela A. Trail, Ph.D,
Regeneron Pharmaceuticals Inc.
Rakesh K. Jain, Ph.D,
Harvard University
Sonya Dougal, Ph.D,
The New York Academy of Sciences
Christopher J. O’Donnell, Ph.D,
Pfizer
Caitlin McOmish, Ph.D,
The New York Academy of Sciences
Laura Saunders, Ph.D,
AbbVie
Greg Thurber, Ph.D
University of Michigan

Note: Poster Abstract Deadline is September 15, 2017

Photo: New York city skyline. Courtesy: © 2017 Fotolia. Used with permission.

Exploring ADC Pharmacokinetics using QSP Modeling Strategies

A webinar presented by Joshua Apgar, Ph.D, Co-Founder and CSO of Applied BioMath, will show how quantitative systems pharmacology (QSP) modeling approaches provided biological insights into the impact of drug-to-antibody (DAR) ratio and the resulting changes in molecular properties on overall pharmacokinetics (PK) and relative payload disposition as observed in preclinical studies.

“We used QSP modeling to explore the PK of antibody-drug conjugate (ADC) therapeutics which typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules,” Apgar said.

“This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex. Modeling helps generate hypotheses that predict this complex behavior,” he noted.

“This ADC case study is a great example of how Model-Aided Drug Invention (MADI) helps project teams quickly discern important characteristics of a platform or drug candidate,” explained John Burke, Ph.D, Co-Founder, President, and CEO of Applied BioMath.

“We often hear from our clients how valuable these biological and drug insights, sometimes counterintuitive, are as it helps accelerate drug candidates into the clinic and to then better ensure the likelihood of testing proof of clinical concept,” Burke added

This webinar will air live at 2pm ET / 11am PT and is ideal for scientists interested in how computational models can be used to design novel ADCs and to optimize the discovery and development of existing ADCs.


Skip to toolbar